ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma

Huang, Shanzhou; Ma, Zuyi; Zhou, Qi; Wang, Aimei; Gong, Yuanfeng; Li, Zhenchong; Wang, Shujie; Yan, Qian; Wang, Dongping*; Hou, Baohua*; Zhang, Chuanzhao*广东省人民医院; 广州医学院; 南方医科大学; 汕头大学; 中山大学; 1; i
International Journal of Biological Sciences2022DOI: 10.7150/ijbs.69969
15被引6阅读
引用收藏
分享

摘要

Background: Lenvatinib is in a first-line therapy for advanced hepatocellular carcinoma (HCC). However, drug resistance is one of the principal obstacles for treatment failure. The molecular mechanism of Lenvatinib resistance has not been well investigated. @@@ Materials and methods: A genome-wide CRISPR/Cas9 knockout screening system was established and bioinformatic analysis was used to identify critical genes associated with Lenvatinib resistance. Cell proliferation assays, colony formation assays and cell migration assays were performed to investigate the effect of drug resistance associated genes, particularly DUSP4, on cancer cell malignant behavior during Lenvatinib treatment. In vivo experiments were conducted by using a xenograft mouse model. @@@ Results: We identified six genes that were associated with Lenvatinib resistance in HCC, including DUSP4, CCBL1, DHDH, CNTN2, NOS3 and TNF. DUSP4 was found to be significantly decreased at the mRNA and protein levels in Lenvatinib resistant HCC cells. DUSP4 knockout enhanced HCC cell survival, cell proliferation and migration during Lenvatinib treatment in vitro and in vivo, accompanied by regulation of p-ERK and p-MEK levels. This finding implied that DUSP4 deficiency induced Lenvatinib resistance. Interestingly, DUSP4 deficiency induced Lenvatinib resistance was abrogated by the MEK inhibitor Selumetinib, implying that MEK phosphorylation and DUSP4-inhibition dependent ERK activation were required for drug resistance. Finally, we found that DUSP4 deficiency was associated with HCC prognosis and response to Lenvatinib based on clinical data. @@@ Conclusions: DUSP4 deficiency mediates Lenvatinib resistance by activating MAPK/ERK signaling and combination therapy using Lenvatinib and MEK inhibitors may be a promising therapeutic strategy for overcoming Lenvatinib resistance.

学科与关键词

关键词
Lenvatinibdrug resistancegenome-wide CRISPR/Cas9 libraryDUSP4MAPK/ERK pathway
相关
加载中…
  • Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
  • Genome-wide CRISPR/Cas9 library screening to identify PAK1 as a critical driver for lenvatinib resistance in HCC.
    Huang, Shanzhou; zhang, chuanzhao; Hou, BaohuaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 1
  • MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
    Xu, Xin; Jiang, Wenjing; Han, Peng; Zhang, Jingyan; Tong, Liquan*; Sun, Xueying*Journal of Hepatocellular Carcinoma, 2022, 9: 113-126.被引 13
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Biological Sciences
发表日期
2022
卷期
第 18 卷, 第 11 期
页码
4357-4371
DOI
10.7150/ijbs.69969
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82102961, 82173149, 82072635, 82072637]; Guangdong Provincial People's Hospital [KY012021164]; Collaborative Funding of Basic and Applied Basis Research Funding of Guangdong Province [2020A1515110536]; Basic and applied basic research funding of Guangdong Province [2021A1515011473, 2021A1515012441]; Science and Technology Program of Guangzhou [202102020030, 202102020107]; Funding for the Construction of Key Specialty in Huizhou

作者

  • H

    Huang, Shanzhou (第一作者)

    2 · guangdong prov peoples hosp · southern med univ

  • M

    Ma, Zuyi

    shantou univ · 2 · guangdong prov peoples hosp

查看全部 11 位作者收起作者
  • Z

    Zhou, Qi

    1 · sun yat sen univ

  • W

    Wang, Aimei

    2 · guangdong prov peoples hosp

  • G

    Gong, Yuanfeng

    2 · guangdong prov peoples hosp · guangzhou med univ · southern med univ

  • L

    Li, Zhenchong

    2 · guangdong prov peoples hosp

  • W

    Wang, Shujie

    2 · guangdong prov peoples hosp · southern med univ

  • Y

    Yan, Qian

    2 · guangdong prov peoples hosp

  • W

    Wang, Dongping (通讯)

    2 · guangdong prov peoples hosp · 1 · i · sun yat sen univ

  • H

    Hou, Baohua (通讯)

    2 · guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, Chuanzhao (通讯)

    2 · guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417